Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
Alnylam Pharmaceuticals (NASDAQ: ALNY) is the leading RNAi therapeutics company, with six approved products (Onpattro, Givlaari, Oxlumo, Amvuttra, Qfitlia, and the Leqvio collaboration with Novartis) and a deep pipeline in cardiometabolic, hepatic infectious disease, and CNS indications. Alnylam's approved medicines target transthyretin amyloidosis (Onpattro, Amvuttra), acute hepatic porphyria (Givlaari), primary hyperoxaluria type 1 (Oxlumo), and hemophilia A and B (Qfitlia). Leqvio (inclisiran), licensed to and commercialized by Novartis, targets LDL cholesterol.
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
Alnylam drafts football veteran for heart disease education push
Alnylam plunges as earnings deliver 'one-two punch'
Alnylam's stock slide deepened as the company reported second-quarter earnings, part of a broader biotech Q2 earnings roundup.
Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock. Reported by Endpoints News on 2026-07-30.
Alnylam Pharmaceuticals faces regulatory scrutiny over promotional practices following a complaint by Pfizer.
Alnylam drew regulatory scrutiny over its promotional activity after a complaint from Pfizer, highlighting ongoing tension between innovators and generic / biosimilar competitors.
Chief Executive Officer